Although the initial rationale for employing these mAbs in the treatment of IBD involved their potential to inhibit CD4+ T cell migration into GALT, recent data suggest that their mode of action may involve other mechanisms [9,59–61]. This evidence concerns the gene CD4 and inflammatory bowel disease.